TB Alliance Launches Five-Country Phase 2 Clinical Trial Evaluating TB Drug
TB Alliance, a New York based global not-for-profit organization, has appointed Ratan P Watal to its board of directors.
NEW YORK, Feb. 23, 2023 /PRNewswire/ -- The TB Alliance Board of Directors has elected David Norton as Chairperson of the Board. In this role, David will provide leadership to a diverse Board committed to advancing the vision of TB Alliance.
Qurient, a clinical-stage biotechnology company based in South Korea, and TB Alliance, a not-for-profit organisation dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs, have entered into a license agreement to develop and commercialise telacebec (Q203), a first-in-class orally available cytochrome bc1 inhibitor for the treatment of tuberculosis (TB) and other non-tuberculosis mycobacterium infections.
Astellas and TB Alliance ink collaborative research pact to identify lead compounds for treatment of nTB
Non-profit drug developer, TB Alliance has granted global pharma major Lupin Limited, a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen.nLupin intends to commercialize the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.
To accelerate the introduction of improved tuberculosis therapeutics, TB Alliance has pioneered the development of novel combinations of TB drugs, instead of single drugs, as the unit of treatment.
Astellas Pharma Inc and TB Alliance, a non-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB) announced that they have entered into a new collaborative research (Hit-to-Lead PJ) agreement to identify lead compounds for the treatment of TB.